logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onPlatformsJoin usTools
 

Genes and Cancer

Links



Research lines

Identifying novel genes altered, at a genetic level, in cancer

Understanding how these abnormalities contribute to cancer development

Identifying molecular markers that determine sensitivity to novel cancer drugs.


 Selected articles (2013-2017) 

  1. Coira IF, Rufino-Palomares EE, Romero OA, Peinado P, Metheetrairut C, Boyero-Corral L, Carretero J, Farez-Vidal E, Cuadros M, Reyes-ZuritaFJ, Lupiáñez JA, Sanchez-Cespedes M, Slack FJ, Medina PP. MiR-155 regulates the expression of the tumor suppressor SMARCA4/BRG1 to contribute to lung cancer. Human Mol Genet 24:1400-9 (2015).
  2. Bonastre E, Verdura S, Zodervan I, Facchinetti F, Lantuejoul S, Chiara MD, Rodrigo JP, Carretero J, Sidransky D, Villanueva A, Condom E, Vidal A, Roz L, Brambilla E, Savola S, Sanchez-Cespedes M. PARD3 inactivation in lung squamous cell carcinomas impairs STAT3 and promotes malignant invasion. Cancer Res. 75: 1287-97 (2015).
  3. George J et al. Comprehensive genomic profiles of small cell lung cancerNature 524:47-53(2015).
  4. Bonastre E, Brambilla E, Sanchez-Cespedes M. Cell adhesion and polarity in squamous cell carcinoma of the lungJ Pathol. 238:606-16 (2016).
  5. Ambrogio et al. Combined inhibition of Ddr1 and Notch signaling as an effective therapeutic strategy for K-Ras-driven/p53-null lung adenocarcinomasNat. Med 22:270-7 (2016).
  6. Jubierre L, Soriano A, Planells-Ferrer L, París-Coderch L, Tenbaum SP, Romero OA, Moubarak RS, Almazán-Moga A, Molist C, Roma J, Navarro S, Noguera R, Sánchez-Céspedes M, Comella JX, Palmer HG, Sánchez de Toledo J, Gallego S, Segura MFBRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways. Oncogene 35: 5179-90 (2016).
  7. Romero OA, Verdura, S, Torrez-Diz M, Gomez T, Moran, S, Condom E, Esteller M, Villanueva A, Sanchez-Cespedes M. Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming. Oncogene 36:1287-96 (2017).
  8. Kato F, Fiorentino FP, Alibés A, Perucho M, Sánchez-Céspedes M, Kohno T, Yokota J. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells. Oncotarget 7:77378-88(2016).
  9. Mateo F, Arenas EJ, Aguilar H, et al. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibitionOncogene Dec 19. (2016).
  10. Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, Graña O, Rubio-Camarillo M, Martinez-Martí A, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sanchez-Cespedes M. Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition. Clin Cancer Res. Dec 21. (2016).
  11. Romero OA Torres-Diz M, Pros E, Gomez A, Moran S, Savola S, Saez C,  Villanueva A, Montuenga LM, Pio R, Thomas RK, Yokota J, Sanchez Cespedes M. MAX inactivation in small-cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1.Cancer Discovery 4:292-303, (2014).
  12. Romero OA, Sanchez-Cespedes M. The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases.Oncogene. 22;33:2681-9 (2014).
  13. Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, Puertas S, Vizoso M, Nadal E, Poggio T, Sánchez-Céspedes M, Esteller M, Mulero F, Voena C, Chiarle R, Barbacid M, Santamaría D, Villanueva A.Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts. Cancer Res.74:5978-88 (2014).
  14. Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, Sanchez-Cespedes M, Assenov Y, Müller F, Bock C, Taron M, Mora J, Muscarella LA, Liloglou T, Davies M, Pollan M, Pajares MJ, Torre W, Montuenga LM, Brambilla E, Field JK, Roz L, Lo Iacono M, Scagliotti GV, Rosell R, Beer DG, Esteller M. A prognostic DNA methylation signature for stage I non-small-cell lung cancer.J Clin Oncol. 31:4140-7 (2013).
  15. Pros E, Lantuejoul S, Sanchez-Verde L, Castillo SD, Bonastre E, Suarez-Gauthier A, Conde E, Cigudosa JC, Lopez-Rios F, Torres-Lanzas J, Castellví J, Ramon y Cajal S, Brambilla E, Sanchez-Cespedes M.Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer. Int J Cancer. 15;133:898-907 (2013).
imatge personal
 

Group leader

Montserrat Sanchez Cespedes
Telephone  
+34 932607132
E-mail  
mscespedes@idibell.cat
 
© 2017 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




Encara no heu contestat l'enquesta de satisfacció sobre la píndola formativa sobre patents. No trigareu més de cinc minuts a fer-ho. La vostra opinió és molt important per millorar l’IDIBELL.

Voleu fer l’enquesta ara?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No





Please, remember to introduce your holiday’s planning in the application

Accept

Cancell